基于细胞通透性嵌合HBV衣壳的可灵活载运抗原的新型黏膜疫苗平台的比较分析
研究比较StrepTag、AviTag、SpyTag与DogTag四种适配器系统将SARS-CoV-2刺突蛋白受体结合域抗原偶联至细胞通透性HBV衣壳载体,发现DogCatcher/DogTag系统在产量、组装、稳定性及抗原装载上最优;小鼠免疫显示偶联抗原免疫反应强于游离抗原,衣壳内载CpG佐剂进一步增强免疫反应,口服/鼻内免疫可诱导显著中和IgG与IgA抗体滴度。
要点
- DogCatcher/DogTag系统在颗粒产量、组装、稳定性及抗原装载方面优于其他适配器系统。
- 偶联载体的抗原诱导的免疫反应强于游离未偶联抗原,衣壳内载CpG佐剂进一步增强免疫反应。
- 载体细胞通透性使口服/鼻内无针免疫可诱导显著中和IgG与IgA抗体滴度。
核心结论
- 该新型平台可作为快速适配针对新发病毒疫苗的灵活基础,其细胞通透性使口服/鼻内途径无针免疫成为可能。
研究设计与样本
- 研究比较StrepTag、AviTag、SpyTag与DogTag适配器系统将SARS-CoV-2刺突蛋白受体结合域抗原偶联至修饰的膜通透性HBV衣壳载体,并对小鼠进行免疫接种。
主要发现
- DogCatcher/DogTag系统在颗粒产量、组装、稳定性及抗原装载至载体表面方面优于其他系统。
- 小鼠免疫显示偶联载体的抗原诱导的免疫反应远强于游离未偶联抗原。
- 衣壳内载CpG佐剂进一步增加免疫反应。
- 口服/鼻内免疫诱导显著滴度的中和IgG与IgA抗体。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The recent SARS-CoV-2 pandemic has demonstrated the importance of vaccines in controlling outbreaks and in preparing for emerging viruses. Platform technologies are highly relevant as they reduce the time taken for vaccine development, market authorisation and production. Here, we present a novel platform based on modified, membrane-permeable hepatitis B virus (HBV) capsids that can flexibly carry various antigens via an adapter. The SARS-CoV2 spike-derived receptor binding domain serves as the antigen. This study aims to identify the most robust system for producing stable carrier/cargo complexes by comparing various platforms. The thereby identified system was used for detailed characterization of the immune response including its capacity for enabling needle free immunization by oral/nasal application. A comparison of various adapter systems (StrepTag, AviTag, SpyTag and DogTag) for coupling the cargo antigen to the cell-permeable capsid as the carrier revealed that the DogCatcher/DogTag system outperforms the others with regard to the yield, assembly and stability of the particles, as well as antigen loading onto the carrier surface. Immunization of mice showed that antigens coupled to the carrier induce a much stronger immune response than free, uncoupled antigens. Loading the capsid interior with CpG as an adjuvant further increased the immune response. Notably, the antigen carrier's cell permeability enables oral/nasal immunization, resulting in significant titres of neutralizing IgG and IgA antibodies. Taken together, this novel platform can be used as a flexible base for quickly adapting vaccines against emerging viruses. Most interestingly, the platform's cell permeability allows for needle-free immunization via the oral/nasal route.
引用
- Raupach J, Housria Y, Hein S, et al. Comparative analysis of a flexible novel vaccine platform based on cell permeable chimeric HBV capsids for mucosal vaccination. Vaccine. 2025. PMID: 41242290. doi:10.1016/j.vaccine.2025.127987
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。